The researchers who engineered the ortholog also packaged it into viral vectors to deliver gene-editing machinery to mouse cells.
The Thermo Fisher subsidiary is not liable to Promega in the US for selling infringing forensic DNA kits in Europe, containing US-manufactured Taq polymerase.
The company will use the funds to work in collaboration with George Mason University to apply its technology to detecting viruses in non-invasive samples.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
The partners will collect cancer tissue samples from volunteers in Tamil Nadu — a region with a population of roughly 78 million.
The company issued preliminary guidance for 2017 of $260 million to $275 million in revenues and adjusted EPS of between $.17 and $.22.
The RNA-based blood test takes less than five hours to detect the presence or absence of infection in patients who may have sepsis.
The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
The company had been warned by Nasdaq in August that it failed to comply with a minimum $10 million stockholder equity requirement to remain listed on the exchange.
The dbGaP was launched in late 2006 to house genotypic and phenotypic data from large-scale genome-wide association studies.
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The assay has been available outside the US since November and runs on the Liaison MDX benchtop instrument.
The funds will help the company prepare for CLIA certification of its lab ahead of the planned launch of its lung cancer test.
The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.
The test kit runs on standard qPCR platforms in under three hours, and detects 20 cancer-associated biomarkers from four oncogenes.
Under the collaboration, Asuragen will develop diagnostic kits for analyzing repeat sequences using Thermo Fisher's 3500 Dx Series Genetic Analyzer CS2 instrument.
The company said it completed 82,000 Cologuard tests during the quarter, a 114 percent growth in test volume during the three-month period.
The collaboration will leverage the firms' technologies to identify patients most likely to develop pancreatic cancer and to detect the cancer in the earliest stage.
Last week, GenomeWeb's readers were most interested in the Broad Institute's early victory in its CRISPR patent battle against the University of California.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
Researchers studying Timema stick insects found that small genetic changes over time due to selective mating could be how individual species evolve.
The funding is being provided through the Massachusetts Life Sciences Center, which oversees the state's $1 billion life sciences investment plan.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.